Forest plot for IL-6. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

The incidence rate of adverse reactions. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

The PRISMA study flowchart. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Forest plot for FEV1/FVC. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Forest plot for clinical efficacy. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Forest plot for FEV1. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

The excluded and included studies were listed. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Forest plot for PaCO₂. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Forest plot for PaO₂. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Image_1_Markers of Pulmonary Oxygen Toxicity in Hyperbaric Oxygen Therapy Using Exhaled Breath Analysis.JPEG by T. T. Wingelaar (6628691)

“…The intensities of PC2, consisting of methyl alkanes, showed a significant decrease (p = 0.001) after the first HBOT session to 50.8%, remained decreased during the subsequent days (mean 82%), and decreased even further after 2 days of rest to 58% (compared to baseline). …”

Image_1_Innovative agroecological practices can restore degraded farmlands and revive crop yields.JPEG by Jules Ntamwira (9683561)

“…When T1 is compared to T3, mean yields increased 2.6 times (848 kg/ha against 327 kg/ha), 2.8 times (2,201 kg/ha against 792 kg/ha) and 1.5 times (7.4 t/ha against 5.0 t/ha) for bean grains, maize grain, and banana bunches, respectively. …”

DataSheet1_Psychotropic Medication Use Before and During COVID-19: A Population-Wide Study.docx by Christine Leong (6429392)

“…</p><p>Results: There were 1,394,885 individuals in the first quarter of 2020, with a mean (SD) age of 38.9 (23.4) years, 50.3% were female, and 36.1% had a psychiatric diagnosis in the previous 5 years. …”

Comprised dendritic arbors in ephrinB1 mutant cortical pyramidal cells. by Dina N. Arvanitis (521401)

“…</i> Sholl analysis of the structure of dendritic arbors. Mean number of dendritic intersections of layer II/III cortical pyramidal neurons show a significant decrease in the number of intersections in pyramidal neurons from <i>EfnB1^Y/−</i> cortex at longer distances from the cell soma. …”

Improvement of the French voicing categorical perception in children with SLI after phonological auditory training by Gregory Collet (7422254)

“…The first blocks were built using stimuli separated by an important acoustical distance: 50 ms (-25 vs +25 msec de VOT). When each child reached 70% of correct response over two blocks, the acoustical distance between the two stimuli decreased (perceptual fading). …”

Data_Sheet_1_Estimation of the economic impact of a bluetongue serotype 4 outbreak in Tunisia.docx by Ameni Ben Salem (18073126)

“…In cattle, exposure to BTV led to a daily unit milk yield decrease of 12.50 to 14.66 L over an average period of 5 months. …”

Overexpression or pharmacological activation of pgk1 rescues motor neuron phenotypes in smn morphant zebrafish. by Penelope J. Boyd (3936893)

“…Note the presence of an axonal outgrowth/branching phenotype associated with <i>smn</i> knockdown (arrow heads) that is reduced in the <i>pgk1</i> over-expressing animals. Scale bars = 50 μM. (B) Overexpression of Pgk1 in <i>smn</i> morphant zebrafish at 30 hpf led to a significant increase in normal motor axons and significant decrease in severe axonal outgrowth phenotypes compared to single <i>smn</i> MO injected embryos. …”

Blue fluorescent cGMP sensor Cygnus. by Yusuke Niino (253286)

“…Half-maximal effective concentration (EC₅₀) values for cGMP and cAMP were 1.0±0.2 µM and 0.4±0.3 mM (means ± s.e.m., <i>n</i> = 4), respectively. …”

AgAR (Agricultural Antibiotic Resistance) by USDA Agricultural Research Service (17476221)

Supplementary Material for: Urinary Biomarkers of Tubular Health and Risk for Kidney Function Decline or Mortality in Diabetes by Chen T.K. (14350107)

“…Methods: We examined associations of five urinary biomarkers of tubular injury and repair (NGAL, KIM-1, IL-18, MCP-1, YKL-40) with kidney function decline (first occurrence of a decrease in eGFR≥30 ml/min/1.73 m2 if randomization eGFR≥60 or ≥50% if randomization eGFR<60; ESKD) and all-cause mortality among 1,135 VA NEPHRON-D trial participants with baseline UACR ≥300 mg/g and available urine samples. …”

Supplementary Material for: Urinary Biomarkers of Tubular Health and Risk for Kidney Function Decline or Mortality in Diabetes by Chen T.K. (14350107)

“…Methods: We examined associations of five urinary biomarkers of tubular injury and repair (NGAL, KIM-1, IL-18, MCP-1, YKL-40) with kidney function decline (first occurrence of a decrease in eGFR≥30 ml/min/1.73 m2 if randomization eGFR≥60 or ≥50% if randomization eGFR<60; ESKD) and all-cause mortality among 1,135 VA NEPHRON-D trial participants with baseline UACR ≥300 mg/g and available urine samples. …”